Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-28T03:04:30.526Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuroleptic-Induced Tardive Cervical Dystonia: Clinical Series of 20 Patients

Published online by Cambridge University Press:  02 December 2014

Clecio Godeiro-Junior ,
Andre C. Felício ,
Patrícia de Carvalho Aguiar ,
Vanderci Borges ,
Sonia M. A. Silva  and
Henrique B. Ferraz
Clecio Godeiro-Junior*
Affiliation:
Department of Neurology and Neurosurgery, Movement Disorders Unit, Federal University of São Paulo, São Paulo, Brazil
Andre C. Felício
Affiliation:
Department of Neurology and Neurosurgery, Movement Disorders Unit, Federal University of São Paulo, São Paulo, Brazil
Patrícia de Carvalho Aguiar
Affiliation:
Department of Neurology and Neurosurgery, Movement Disorders Unit, Federal University of São Paulo, São Paulo, Brazil
Vanderci Borges
Affiliation:
Department of Neurology and Neurosurgery, Movement Disorders Unit, Federal University of São Paulo, São Paulo, Brazil
Sonia M. A. Silva
Affiliation:
Department of Neurology and Neurosurgery, Movement Disorders Unit, Federal University of São Paulo, São Paulo, Brazil
Henrique B. Ferraz
Affiliation:
Department of Neurology and Neurosurgery, Movement Disorders Unit, Federal University of São Paulo, São Paulo, Brazil
*
Rua Dr Diogo de Faria, 650, ap. 33, Vila Clementino, Postal Code 04037-002, SãPaulo, SãPaulo, Brazil
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Cervical dystonia (CD) may be classified according to the underlying cause into primary or secondary CD. Previous exposure to neuroleptics is one of the main causes of adult-onset secondary dystonia. There are few reports that characterize the clinical features of primary CD and secondary neuroleptic-induced CD. Herein our aim was to investigate a series of patients with neuroleptic induced tardive CD and to describe their clinical and demographic features.

Patients and Methods:

We retrospectively evaluated 20 patients with neuroleptic-induced tardive CD and compared clinical, demographic and therapeutic characteristics to another 77 patients with primary CD. All patients underwent Botulinum toxin type-A therapy.

Results:

We did not identify any relevant clinical and demographic characteristics in our group of patients that could be used to distinguish tardive and primary CD.

Conclusion:

Patients with tardive CD presented demographic characteristics and disease course similar to those with primary CD.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 36 , Issue 2 , March 2009 , pp. 222 - 226
Copyright
Copyright © The Canadian Journal of Neurological 2009

References

1.Nutt, JG, Muenter, MD, Aranson, A, Kurland, LT, Melton, LJ.Epidemiology of focal and generalized dystonia in Rochester Minessota. Mov Disord. 1988;3(3):188–94.Google Scholar
2.de Carvalho Aguiar, PM, Ozelius, LJ.Classification and genetics of dystonia. Lancet Neurol. 2002;1(5):316–25.Google Scholar
3.Burke, SE, Fahn, S, Jankovic, J, Marsden, CD, Lang, AE, Gollomp, S, et al.Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32(12):1335–46.Google Scholar
4.Camargo, CH, Teive, HA, Becker, N, Baran, MH, Scola, RH, Werneck, LC.Cervical dystonia: clinical and therapeutic features in 85 patients. Arq Neuropsiquiatr. 2008;66(1):15–21.Google Scholar
5.Kang, UJ, Burke, RE, Fahn, S.Natural history and treatment of tardive dystonia. Mov Disord. 1986;1(3):193–208.CrossRefGoogle ScholarPubMed
6.Ferraz, HB, Andrade, LA.Symptomatic dystonia: clinical profile of 46 Brazilian patients. Can J Neurol Sci. 1992;19(4):504–7.Google Scholar
7.Molho, ES, Feustel, PJ, Factor, SA.Clinical comparison of tardive and idiopathic cervical dystonia. Mov Disord. 1998;13(3):486–9.Google Scholar
8.Tsui, JK, Eisen, A, Stoessl, AJ, Calne, S, Calne, DB.Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2(8501):245–7.Google Scholar
9.Jahanshahi, M, Marion, MH, Marsden, D.Natural history of adult-onset idiopathic torticollis. Arch Neurol. 1990;47(5):548–52.Google Scholar
10.Kiriakakis, V, Bhatia, KP, Quinn, NP, Marsden, CD.The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 1998;121(11):2053–66.Google Scholar
11.Brashear, A, Ambrosius, WT, Eckert, GJ, Siemers, ER.Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord. 1998;13(1):158–61.Google Scholar
12.Havaki-Kontaxaki, BJ, Kontaxakis, VP, Margariti, MM, Paplos, KG, Christodoulou, GN.Treatment of severe neuroleptic-induced tardive torticollis. Ann Gen Hosp Psychiatry. 2003;2(1):9.Google Scholar
13.Tarsy, D, Kaufman, D, Sehti, KD, Rivner, ME, Molho, E, Factor, S.An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol. 1997;20(1):90–3.Google Scholar
14.Chatterjee, A, Forrest, GM, Giladi, N, Trosh, R.Botulinum toxin in the treatment of tardive dystonia. J Clin Psychopharmacol. 1997;17(6):497–8.CrossRefGoogle ScholarPubMed